Importance Among patients younger than 21 years of age, the optimal duration of
anticoagulant therapy for venous thromboembolism is unknown. Objective To test the …

Summary Background Randomized controlled trials (RCTs) on pediatric venous
thromboembolism (VTE) treatment have been challenged by unsubstantiated design …

Background The long‐term risk for recurrent venous thromboembolism (VTE) during
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine …

Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …

Background The optimal duration of oral anticoagulant therapy after a first episode of
venous thromboembolism is still a matter of debate. Methods We performed a multicenter …

Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP (Hôpital Edouard Herriot
and Unité de Pharmacologie Clinique, Lyon, France). J Intern Med 2000; 247: 553–562 …

Randomized controlled trials are the optimal study design to compare management
strategies, including comparisons of different durations of anticoagulant therapy for venous …

Background Patients who have a first episode of venous thromboembolism in the absence
of known risk factors for thrombosis (idiopathic thrombosis) are often treated with …

The balance between the efficacy and safety of anticoagulant therapy in patients aged≥ 90
years with venous thromboembolism (VTE) is uncertain. RIETE is an ongoing, prospective …

Background Currently, little evidence is available on the length and type of anticoagulation
used for extended treatment for prevention of recurrent venous thromboembolism (VTE) in …